ArticleFrontiers in oncology2026
Case Report: High-grade endometrial adenocarcinoma with somatically derived yolk sac tumor differentiation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yolk sac tumors (YSTs) arising from somatic tumors of the female genital tract present with variable clinical manifestations depending on the organ of origin. Their diagnosis is highly challenging due to their rarity and the limited number of well-documented cases, and their prognosis remains unclear. The coexistence of high-grade endometrial adenocarcinoma with somatically derived yolk sac tumor differentiation (SDYST) is extremely rare, and evidence-based treatment strategies remain limited. Case highlights: A 44-year-old premenopausal woman presented with abnormal uterine bleeding predominantly characterized by menorrhagia for approximately two months. Following surgical staging, pathological examination revealed high-grade endometrial adenocarcinoma with SDYST. Immunohistochemistry (IHC) showed positivity for SALL4 and Glypican-3 (GPC3), with focal expression of alpha-fetoprotein (AFP). Serum AFP levels were markedly elevated. Follow-up and outcomes: The patient recovered well postoperatively. After multidisciplinary evaluation, she received BEP-based chemotherapy, and serum AFP levels were dynamically monitored. Serum AFP decreased markedly during treatment, and no definite evidence of disease progression was observed during short-term follow-up. Lessons: This case provides a practical clinical lesson: markedly elevated serum AFP in an aggressive endometrial tumor should prompt consideration of SDYST, particularly when yolk sac tumor-like morphology and positive immunohistochemical staining for AFP, SALL4, and GPC3 are present. Early recognition of this phenotype may facilitate appropriate immunohistochemical workup, AFP-based disease monitoring, and timely multidisciplinary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.